Related Experiment Video
Updated: Nov 9, 2025

Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments
Published on: May 9, 2019
Bisphosphonate application and volumetric effects on MRONJ lesions
Max-Philipp Lentzen1, Johannes Buller1, Maximilian Riekert1
1Department for Oral and Craniomaxillofacial and Plastic Surgery, University Hospital Cologne and Faculty of Medicine, University of Cologne, Germany.
Abstract:
The purpose of this investigation was to analyze the volume of medication-related osteonecrosis of the jaw (MRONJ) lesions by semi-automatic segmentation of cone-beam computed tomography images, and correlate the results with the underlying diseases and applied medication. MRONJ lesions detected in cone-beam computed tomography images were assessed. The open-source software ITK-Snap enabled volumetric measurements of MRONJ lesions based on semi-automatic segmentation. Results were analyzed according to necrosis volume, localization, and gender. In addition, the underlying disease and the type of application of antiresorptive medication were investigated. Cone-beam computed tomography images of 66 patients were studied. 34 male and 32 female patients were included, with ages ranging from 50 to 93 years at the time of diagnosis. The mean volume was 993.24 ± 620.94 mm3: 484.73 ± 230.97 mm3 for the upper jaw and 1084.04 ± 625.74 mm3 for the lower jaw. The results indicated statistically significant differences between lesions of the upper and lower jaw, regardless of gender (p = 0.003). The analysis of differences between males and females did not show any significant results (p = 0.464), although males presented slightly larger lesions than females. With regard to the underlying disease, patients with osteoporosis presented larger volumes, whereas patients with malignant tumors presented smaller volumes. Nevertheless, no statistically significant differences according to the underlying disease (p = 0.313) were detected. However, patients with intravenous (iv) application showed statistically significantly larger lesions than patients who underwent oral or subcutaneous (s.c.) applications (p = 0.004). It seems that the osteonecrosis volume correlates with the applied antiresorptive agents. Larger MRONJ lesions should be expected in patients who receive intravenous antiresorptive therapy.
Insights
Medication-related osteonecrosis of the jaw (MRONJ) lesion volumes were measured using CT scans. Intravenous antiresorptive medication correlated with significantly larger MRONJ lesions compared to oral or subcutaneous routes.
Area of Science:
- Oral and Maxillofacial Surgery
- Radiology
- Pharmacology
Background:
- Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication of antiresorptive therapy.
- Accurate volumetric assessment of MRONJ lesions is crucial for understanding disease progression and treatment efficacy.
Purpose of the Study:
- To analyze the volume of MRONJ lesions using semi-automatic segmentation of cone-beam computed tomography (CBCT) images.
- To correlate lesion volume with underlying diseases and the route of antiresorptive medication administration.
Main Methods:
- Semi-automatic segmentation of MRONJ lesions was performed on CBCT images using ITK-Snap software.
- Volumetric measurements were analyzed based on lesion size, location, gender, underlying disease, and medication application route.
- CBCT scans from 66 patients (34 male, 32 female) were included in the study.
Main Results:
- Mean MRONJ lesion volume was 993.24 mm³ (upper jaw: 484.73 mm³; lower jaw: 1084.04 mm³).
- Statistically significant differences in lesion volume were observed between the upper and lower jaws (p=0.003).
- Intravenous (IV) antiresorptive administration resulted in significantly larger MRONJ lesions compared to oral or subcutaneous (s.c.) routes (p=0.004).
Conclusions:
- The volume of MRONJ lesions is influenced by the route of antiresorptive medication delivery.
- Patients receiving intravenous antiresorptive therapy are likely to develop larger MRONJ lesions.
- Further research may explore specific antiresorptive agents and their impact on MRONJ lesion volume.
Related Concept Videos
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Drug Distribution: Tissue Binding
For...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...

